No Data
Spyre Therapeutics Announces Grants of Inducement Awards
Express News | Spyre Therapeutics Appoints DR. Sheldon Sloan as Chief Medical Officer
Press Release: Spyre Therapeutics Appoints Dr. Sheldon Sloan as Chief Medical Officer
BTIG Maintains Spyre Therapeutics(SYRE.US) With Buy Rating, Maintains Target Price $40
Spyre Therapeutics Poised for Market Leadership With Promising IBD Drug Candidates
LifeSci Capital Maintains Spyre Therapeutics(SYRE.US) With Buy Rating, Maintains Target Price $50
LifeSci Capital analyst Sam Slutsky maintains $Spyre Therapeutics(SYRE.US)$ with a buy rating, and maintains the target price at $50.According to TipRanks data, the analyst has a success rate of 47.5%